Gagal Jantung Akut
Published on September 21, 2026
Risk Factors
Pre-existing chronic heart failure, coronary artery disease, hypertension, diabetes mellitus, chronic kidney disease, atrial fibrillation, valvular heart disease, obesity, dietary or medication nonadherence
Etiology
Decompensation of chronic HF (most common trigger), acute coronary syndrome, hypertensive emergency, new-onset arrhythmia, acute valvular pathology (e.g., acute mitral regurgitation from chordae tendinae rupture), myocarditis, acute volume overload (renal failure, excessive IV fluids)
Presentation
Progressive dyspnea on exertion, orthopnea ("uses 3 pillows to sleep"), paroxysmal nocturnal dyspnea ("wakes up at night gasping for air"), weight gain over days, bilateral lower extremity swelling
Classic Exam
Jugular venous distension (JVD), bilateral pulmonary crackles/rales, S3 gallop on auscultation, bilateral pitting edema, hepatojugular reflux, displaced PMI (in dilated cardiomyopathy), cool/clammy extremities (if low output)
Diagnostics
Elevated BNP (>100 pg/mL) or NT-proBNP (>300 pg/mL); CXR showing cephalization of vessels, Kerley B lines, bilateral pleural effusions, cardiomegaly; echocardiography showing reduced or preserved EF with diastolic dysfunction
Management
IV loop diuretics (furosemide) as first-line; IV vasodilators (nitroglycerin) if hypertensive; inotropes (dobutamine) or vasopressors (norepinephrine) if cardiogenic shock; non-invasive positive pressure ventilation for respiratory distress; long-term guideline-directed medical therapy after stabilization
Keywords
"Can't lay flat," "3-pillow orthopnea," "wakes up gasping," "10 lb weight gain in one week," "bilateral crackles," "S3 gallop," "JVD," "missed medications," "dietary indiscretion"
01Pathophysiology
Acute heart failure (AHF) represents a clinical syndrome in which the heart is unable to maintain adequate cardiac output to meet the body's metabolic demands, or can only do so at the cost of elevated filling pressures. It may present as a new-onset event or, more commonly, as an acute decompensation of pre-existing chronic heart failure. The key to understanding every symptom and sign lies in two interconnected concepts: forward failure (inadequate perfusion) and backward failure (congestion).
In forward failure, the left ventricle cannot pump sufficient blood into the systemic circulation. This leads to decreased tissue perfusion, manifesting as fatigue, altered mental status, oliguria, and cool extremities. When forward failure is severe enough to cause end-organ hypoperfusion with systolic blood pressure below 90 mmHg, the patient has crossed into cardiogenic shock, which carries a high mortality rate.
In backward failure, blood backs up behind the failing ventricle. When the left ventricle fails, elevated left atrial and pulmonary venous pressures cause transudation of fluid into the pulmonary interstitium and alveoli. This is why patients develop dyspnea, orthopnea, and paroxysmal nocturnal dyspnea (PND). The crackles heard on lung auscultation directly reflect this fluid accumulation. When the right ventricle fails (or when left-sided failure transmits backward through the pulmonary vasculature), elevated systemic venous pressures cause JVD, hepatomegaly, ascites, and peripheral edema.
The neurohormonal response plays a central role in the pathophysiologic spiral. Decreased cardiac output triggers the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS). While initially compensatory (increasing heart rate, contractility, and intravascular volume), sustained activation leads to progressive myocardial remodeling, vasoconstriction, sodium and water retention, and worsening failure. This is the rationale for using ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists in long-term management: they interrupt this maladaptive neurohormonal cycle.
Flash pulmonary edema is a distinct and dramatic presentation where acute, severe pulmonary congestion develops over minutes rather than days. This is classically seen in acute hypertensive crisis, acute mitral regurgitation (e.g., papillary muscle rupture post-MI), or bilateral renal artery stenosis. The mechanism here is a rapid increase in left-sided filling pressures overwhelming the pulmonary capillary barrier.
02Classification and Clinical Manifestation
By Ejection Fraction
HFrEF (Heart Failure with Reduced EF)
Ejection Fraction
EF ≤ 40%
Key Features
Systolic dysfunction; the ventricle cannot contract effectively; most evidence-based therapies target this group
HFmrEF (Mildly Reduced EF)
Ejection Fraction
EF 41-49%
Key Features
Intermediate category; emerging data suggest benefit from HFrEF therapies
HFpEF (Preserved EF)
Ejection Fraction
EF ≥ 50%
Key Features
Diastolic dysfunction; the ventricle is stiff and cannot relax/fill properly; common in elderly, hypertensive, obese patients; fewer proven therapies (SGLT2 inhibitors now have evidence here)
Category | Ejection Fraction | Key Features |
|---|---|---|
HFrEF (Heart Failure with Reduced EF) | EF ≤ 40% | Systolic dysfunction; the ventricle cannot contract effectively; most evidence-based therapies target this group |
HFmrEF (Mildly Reduced EF) | EF 41-49% | Intermediate category; emerging data suggest benefit from HFrEF therapies |
HFpEF (Preserved EF) | EF ≥ 50% | Diastolic dysfunction; the ventricle is stiff and cannot relax/fill properly; common in elderly, hypertensive, obese patients; fewer proven therapies (SGLT2 inhibitors now have evidence here) |
NYHA Functional Classification
Class | Symptoms |
|---|---|
I | No limitation of physical activity; ordinary activity does not cause symptoms |
II | Slight limitation; comfortable at rest, but ordinary activity results in dyspnea, fatigue, or palpitations |
III | Marked limitation; comfortable at rest, but less-than-ordinary activity causes symptoms |
IV | Unable to carry out any physical activity without discomfort; symptoms at rest |
Hemodynamic Profiles (Stevenson Classification)
This is the most high-yield classification for acute management because it directly determines therapy.
Warm and Dry (Compensated)
Perfusion (Warm vs. Cold)
Adequate perfusion
Congestion (Dry vs. Wet)
No congestion
Clinical Features
Well-perfused, no edema, no rales
Treatment Approach
Optimize oral GDMT; this is the goal state
Warm and Wet (Most Common AHF Presentation)
Perfusion (Warm vs. Cold)
Adequate perfusion
Congestion (Dry vs. Wet)
Congested
Clinical Features
Warm extremities, JVD, crackles, edema, adequate BP
Treatment Approach
IV diuretics +/- vasodilators
Cold and Wet (Low-Output with Congestion)
Perfusion (Warm vs. Cold)
Poor perfusion
Congestion (Dry vs. Wet)
Congested
Clinical Features
Cool/mottled extremities, hypotension, oliguria, AND JVD, crackles, edema
Treatment Approach
Inotropes (dobutamine/milrinone) + diuretics; may need vasopressors
Cold and Dry (Low-Output without Congestion)
Perfusion (Warm vs. Cold)
Poor perfusion
Congestion (Dry vs. Wet)
No congestion
Clinical Features
Cool extremities, hypotension, but no edema or rales; often over-diuresed
Treatment Approach
Cautious volume challenge +/- inotropes; hold diuretics
Profile | Perfusion (Warm vs. Cold) | Congestion (Dry vs. Wet) | Clinical Features | Treatment Approach |
|---|---|---|---|---|
Warm and Dry (Compensated) | Adequate perfusion | No congestion | Well-perfused, no edema, no rales | Optimize oral GDMT; this is the goal state |
Warm and Wet (Most Common AHF Presentation) | Adequate perfusion | Congested | Warm extremities, JVD, crackles, edema, adequate BP | IV diuretics +/- vasodilators |
Cold and Wet (Low-Output with Congestion) | Poor perfusion | Congested | Cool/mottled extremities, hypotension, oliguria, AND JVD, crackles, edema | Inotropes (dobutamine/milrinone) + diuretics; may need vasopressors |
Cold and Dry (Low-Output without Congestion) | Poor perfusion | No congestion | Cool extremities, hypotension, but no edema or rales; often over-diuresed | Cautious volume challenge +/- inotropes; hold diuretics |
Clinical Presentations of Acute Heart Failure
Acute Decompensated CHF
Key Feature
Gradual worsening of chronic HF over days to weeks; peripheral edema, weight gain, orthopnea
Typical Hemodynamics
Warm and wet (most common)
Acute Pulmonary Edema / Flash Pulmonary Edema
Key Feature
Sudden-onset severe dyspnea, pink frothy sputum, diffuse crackles, hypoxemia
Typical Hemodynamics
Elevated BP often (hypertensive emergency), rapid fluid redistribution
Cardiogenic Shock
Key Feature
Hypotension (SBP <90), end-organ hypoperfusion (AMS, oliguria, cool extremities), tachycardia
Typical Hemodynamics
Cold and wet
Isolated Right Heart Failure
Key Feature
JVD, hepatomegaly, peripheral edema, clear lungs
Typical Hemodynamics
Right-sided congestion without pulmonary edema
Presentation | Key Feature | Typical Hemodynamics |
|---|---|---|
Acute Decompensated CHF | Gradual worsening of chronic HF over days to weeks; peripheral edema, weight gain, orthopnea | Warm and wet (most common) |
Acute Pulmonary Edema / Flash Pulmonary Edema | Sudden-onset severe dyspnea, pink frothy sputum, diffuse crackles, hypoxemia | Elevated BP often (hypertensive emergency), rapid fluid redistribution |
Cardiogenic Shock | Hypotension (SBP <90), end-organ hypoperfusion (AMS, oliguria, cool extremities), tachycardia | Cold and wet |
Isolated Right Heart Failure | JVD, hepatomegaly, peripheral edema, clear lungs | Right-sided congestion without pulmonary edema |
03Diagnostic Workup
BNP / NT-proBNP
Role
Best Initial Test (screening/triage)
Key Findings
BNP >100 pg/mL or NT-proBNP >300 pg/mL supports HF diagnosis; very high values (BNP >400, NT-proBNP >900-1800 based on age) strongly suggest AHF; normal values effectively rule out AHF (high negative predictive value)
Chest X-ray
Role
Best Initial Imaging
Key Findings
Cephalization of pulmonary vessels, Kerley B lines, peribronchial cuffing, bilateral pleural effusions, "bat-wing" pulmonary edema, cardiomegaly (cardiothoracic ratio >0.5)
12-lead ECG
Role
Routine, done immediately
Key Findings
Evaluate for ischemia (ST changes), arrhythmia (atrial fibrillation, VT), LVH, bundle branch block; a completely normal ECG makes systolic HF unlikely
Echocardiography
Role
Most Accurate / Confirmatory Test
Key Findings
Assess EF (reduced vs. preserved), wall motion abnormalities, valvular pathology, chamber sizes, diastolic function, pericardial effusion
Troponin
Role
Rule out ACS as precipitant
Key Findings
May be mildly elevated in AHF from demand ischemia; significantly elevated troponin suggests ACS as the trigger
Basic Metabolic Panel
Role
Routine
Key Findings
Assess renal function (creatinine, BUN), electrolytes (hyponatremia carries poor prognosis in HF, hypo/hyperkalemia)
CBC
Role
Routine
Key Findings
Evaluate for anemia (high-output precipitant) or infection
TSH
Role
Consider in new-onset HF
Key Findings
Hyperthyroidism or severe hypothyroidism can cause or exacerbate HF
Liver Function Tests
Role
If right-sided HF suspected
Key Findings
Congestive hepatopathy causes elevated AST, ALT, and bilirubin
Arterial Blood Gas
Role
If significant respiratory distress
Key Findings
Assess oxygenation, ventilation, and acid-base status
Right Heart Catheterization (Swan-Ganz)
Role
Refractory or unclear cases
Key Findings
Direct measurement of PCWP, cardiac output, and systemic vascular resistance; helps distinguish cardiogenic from non-cardiogenic causes; not routinely needed
Test | Role | Key Findings |
|---|---|---|
BNP / NT-proBNP | Best Initial Test (screening/triage) | BNP >100 pg/mL or NT-proBNP >300 pg/mL supports HF diagnosis; very high values (BNP >400, NT-proBNP >900-1800 based on age) strongly suggest AHF; normal values effectively rule out AHF (high negative predictive value) |
Chest X-ray | Best Initial Imaging | Cephalization of pulmonary vessels, Kerley B lines, peribronchial cuffing, bilateral pleural effusions, "bat-wing" pulmonary edema, cardiomegaly (cardiothoracic ratio >0.5) |
12-lead ECG | Routine, done immediately | Evaluate for ischemia (ST changes), arrhythmia (atrial fibrillation, VT), LVH, bundle branch block; a completely normal ECG makes systolic HF unlikely |
Echocardiography | Most Accurate / Confirmatory Test | Assess EF (reduced vs. preserved), wall motion abnormalities, valvular pathology, chamber sizes, diastolic function, pericardial effusion |
Troponin | Rule out ACS as precipitant | May be mildly elevated in AHF from demand ischemia; significantly elevated troponin suggests ACS as the trigger |
Basic Metabolic Panel | Routine | Assess renal function (creatinine, BUN), electrolytes (hyponatremia carries poor prognosis in HF, hypo/hyperkalemia) |
CBC | Routine | Evaluate for anemia (high-output precipitant) or infection |
TSH | Consider in new-onset HF | Hyperthyroidism or severe hypothyroidism can cause or exacerbate HF |
Liver Function Tests | If right-sided HF suspected | Congestive hepatopathy causes elevated AST, ALT, and bilirubin |
Arterial Blood Gas | If significant respiratory distress | Assess oxygenation, ventilation, and acid-base status |
Right Heart Catheterization (Swan-Ganz) | Refractory or unclear cases | Direct measurement of PCWP, cardiac output, and systemic vascular resistance; helps distinguish cardiogenic from non-cardiogenic causes; not routinely needed |
The workup begins at the bedside. When a patient presents with acute dyspnea, the first priority is to determine whether heart failure is the cause or whether you are dealing with a pulmonary process such as COPD exacerbation, pneumonia, or pulmonary embolism. The best initial test for this triage is the BNP or NT-proBNP. These natriuretic peptides are released by ventricular myocytes in response to volume overload and wall stress. A BNP below 100 pg/mL (or NT-proBNP below 300 pg/mL) has a negative predictive value exceeding 95%, making it an excellent rule-out test. However, note that BNP can be falsely low in obesity and flash pulmonary edema (too rapid for peptide release), and falsely elevated in renal failure, atrial fibrillation, advanced age, and sepsis.
A chest X-ray should be obtained simultaneously. The classic radiographic progression of worsening left-sided heart failure follows a predictable pattern: first, cephalization (redistribution of blood flow to the upper lobes), then interstitial edema (Kerley B lines, peribronchial cuffing), then alveolar edema ("bat-wing" or "butterfly" pattern), and finally bilateral pleural effusions. Cardiomegaly (cardiothoracic ratio >0.5 on PA film) supports the diagnosis. Be aware that in acute, rapid-onset pulmonary edema, the CXR may show pulmonary congestion without cardiomegaly because the heart has not had time to dilate.
An ECG is obtained in every patient with acute dyspnea. In the context of AHF, you are looking for ST-segment changes suggesting acute ischemia (which would make ACS the precipitant), atrial fibrillation with rapid ventricular response (a common trigger for decompensation), left ventricular hypertrophy, or left bundle branch block. A completely normal ECG in a patient suspected of heart failure should make you reconsider the diagnosis, as its negative predictive value for systolic dysfunction is high.
Transthoracic echocardiography is the most accurate test and should be obtained within 48 hours (or emergently if the patient is hemodynamically unstable). It provides the definitive assessment of ejection fraction, chamber dimensions, wall motion abnormalities (pointing to ischemic etiology), valvular dysfunction, and diastolic filling parameters. This is the test that classifies the patient into HFrEF, HFmrEF, or HFpEF and guides long-term therapy decisions.
Troponin should be checked in all patients presenting with AHF. A significant elevation raises concern for acute coronary syndrome as the precipitating event and would change management toward urgent catheterization. Mild elevations may be seen from demand ischemia (type 2 MI) in the setting of tachycardia and elevated wall stress.
Right heart catheterization with a Swan-Ganz catheter is reserved for patients who are refractory to initial therapy or when the hemodynamic profile is unclear. It directly measures pulmonary capillary wedge pressure (PCWP, elevated >18 mmHg in cardiogenic pulmonary edema), cardiac index, and systemic vascular resistance. This is not routine and should not be the first-line test on an exam question.
04Management and Treatment
Summary Table: Acute Stabilization
Warm and Wet (adequate BP, congested)
First-Line Therapy
IV furosemide 20-40 mg bolus (diuretic-naive) or 1 to 2.5x home oral dose given IV
Additional Therapies
Add IV nitroglycerin (start 5-10 mcg/min, titrate q5min) if persistent hypertension or ongoing dyspnea; consider nitroprusside for severe afterload reduction
Hypertensive Pulmonary Edema (SBP >140)
First-Line Therapy
IV nitroglycerin or nitroprusside for aggressive afterload reduction
Additional Therapies
IV furosemide concurrently; non-invasive positive pressure ventilation (BiPAP preferred)
Cold and Wet (hypotensive, congested)
First-Line Therapy
IV dobutamine (2-20 mcg/kg/min) to augment cardiac output
Additional Therapies
Add IV furosemide once perfusion improves; if SBP <80-85, add norepinephrine (0.1-0.5 mcg/kg/min) before or alongside dobutamine
Cold and Dry (hypotensive, not congested)
First-Line Therapy
Cautious IV fluid challenge (250 mL bolus, reassess)
Additional Therapies
If no response, consider inotropes; hold all diuretics
Cardiogenic Shock
First-Line Therapy
Norepinephrine (first-line vasopressor per current guidelines) + dobutamine for inotropy
Additional Therapies
Consider mechanical circulatory support (IABP, Impella, ECMO) if refractory; emergent revascularization if ACS is the cause
Respiratory Distress / Hypoxemia
First-Line Therapy
Supplemental oxygen (target SpO2 ≥ 94%); if inadequate, non-invasive ventilation (CPAP or BiPAP)
Additional Therapies
Intubation and mechanical ventilation if non-invasive ventilation fails or patient is obtunded
Scenario | First-Line Therapy | Additional Therapies |
|---|---|---|
Warm and Wet (adequate BP, congested) | IV furosemide 20-40 mg bolus (diuretic-naive) or 1 to 2.5x home oral dose given IV | Add IV nitroglycerin (start 5-10 mcg/min, titrate q5min) if persistent hypertension or ongoing dyspnea; consider nitroprusside for severe afterload reduction |
Hypertensive Pulmonary Edema (SBP >140) | IV nitroglycerin or nitroprusside for aggressive afterload reduction | IV furosemide concurrently; non-invasive positive pressure ventilation (BiPAP preferred) |
Cold and Wet (hypotensive, congested) | IV dobutamine (2-20 mcg/kg/min) to augment cardiac output | Add IV furosemide once perfusion improves; if SBP <80-85, add norepinephrine (0.1-0.5 mcg/kg/min) before or alongside dobutamine |
Cold and Dry (hypotensive, not congested) | Cautious IV fluid challenge (250 mL bolus, reassess) | If no response, consider inotropes; hold all diuretics |
Cardiogenic Shock | Norepinephrine (first-line vasopressor per current guidelines) + dobutamine for inotropy | Consider mechanical circulatory support (IABP, Impella, ECMO) if refractory; emergent revascularization if ACS is the cause |
Respiratory Distress / Hypoxemia | Supplemental oxygen (target SpO2 ≥ 94%); if inadequate, non-invasive ventilation (CPAP or BiPAP) | Intubation and mechanical ventilation if non-invasive ventilation fails or patient is obtunded |
Summary Table: Long-Term Guideline-Directed Medical Therapy (GDMT) for HFrEF
ACEi / ARB / ARNI
Examples
Enalapril 2.5-20 mg BID; Losartan 25-150 mg daily; Sacubitril/Valsartan (ARNI) 24/26 mg to 97/103 mg BID
Dosing
ARNI is preferred over ACEi/ARB if tolerated; allow 36-hour washout when switching from ACEi to ARNI to prevent angioedema
Key Notes
Contraindicated in bilateral renal artery stenosis, pregnancy, hyperkalemia, angioedema history (ACEi)
Beta-Blockers
Examples
Carvedilol 3.125-25 mg BID; Metoprolol succinate 12.5-200 mg daily; Bisoprolol 1.25-10 mg daily
Dosing
Only these three are evidence-based for HFrEF mortality reduction
Key Notes
Do NOT initiate during acute decompensation; start only when patient is euvolemic and stable; if already on a beta-blocker at home, continue at reduced dose unless in cardiogenic shock
Mineralocorticoid Receptor Antagonist (MRA)
Examples
Spironolactone 12.5-50 mg daily; Eplerenone 25-50 mg daily
Dosing
For NYHA II-IV with EF ≤35%
Key Notes
Contraindicated if K+ >5.0 mEq/L or CrCl <30 mL/min; monitor potassium closely
SGLT2 Inhibitor
Examples
Dapagliflozin 10 mg daily; Empagliflozin 10 mg daily
Dosing
Benefit independent of diabetes status; also proven in HFpEF
Key Notes
Avoid in type 1 diabetes; monitor for genital infections, euglycemic DKA
Hydralazine + Isosorbide Dinitrate
Examples
Hydralazine 25-75 mg TID + Isosorbide dinitrate 20-40 mg TID
Dosing
Specifically indicated in Black patients (A-HeFT trial) or as an alternative if ACEi/ARB/ARNI is contraindicated
Key Notes
Not a first-line substitute for RAAS inhibition in other populations unless necessary
Ivabradine
Examples
5-7.5 mg BID
Dosing
For patients with EF ≤35% in sinus rhythm with resting HR ≥70 bpm despite maximally tolerated beta-blocker
Key Notes
Does not work in atrial fibrillation (requires sinus rhythm)
Loop Diuretics (chronic)
Examples
Furosemide 20-80 mg daily/BID; Bumetanide 0.5-2 mg daily/BID; Torsemide 10-20 mg daily
Dosing
For symptom relief and volume management only; no mortality benefit
Key Notes
Adjust dose based on daily weight and fluid status
ICD
Examples
N/A
Dosing
Primary prevention ICD for EF ≤35% despite ≥3 months of optimal GDMT, NYHA II-III, expected survival >1 year
Key Notes
Do NOT place during the acute hospitalization; reassess EF after optimization
CRT (Cardiac Resynchronization Therapy)
Examples
N/A
Dosing
For EF ≤35% + LBBB with QRS ≥150 ms + NYHA II-IV on optimal GDMT
Key Notes
Greatest benefit with LBBB morphology and QRS ≥150 ms
Drug Class | Examples | Dosing | Key Notes |
|---|---|---|---|
ACEi / ARB / ARNI | Enalapril 2.5-20 mg BID; Losartan 25-150 mg daily; Sacubitril/Valsartan (ARNI) 24/26 mg to 97/103 mg BID | ARNI is preferred over ACEi/ARB if tolerated; allow 36-hour washout when switching from ACEi to ARNI to prevent angioedema | Contraindicated in bilateral renal artery stenosis, pregnancy, hyperkalemia, angioedema history (ACEi) |
Beta-Blockers | Carvedilol 3.125-25 mg BID; Metoprolol succinate 12.5-200 mg daily; Bisoprolol 1.25-10 mg daily | Only these three are evidence-based for HFrEF mortality reduction | Do NOT initiate during acute decompensation; start only when patient is euvolemic and stable; if already on a beta-blocker at home, continue at reduced dose unless in cardiogenic shock |
Mineralocorticoid Receptor Antagonist (MRA) | Spironolactone 12.5-50 mg daily; Eplerenone 25-50 mg daily | For NYHA II-IV with EF ≤35% | Contraindicated if K+ >5.0 mEq/L or CrCl <30 mL/min; monitor potassium closely |
SGLT2 Inhibitor | Dapagliflozin 10 mg daily; Empagliflozin 10 mg daily | Benefit independent of diabetes status; also proven in HFpEF | Avoid in type 1 diabetes; monitor for genital infections, euglycemic DKA |
Hydralazine + Isosorbide Dinitrate | Hydralazine 25-75 mg TID + Isosorbide dinitrate 20-40 mg TID | Specifically indicated in Black patients (A-HeFT trial) or as an alternative if ACEi/ARB/ARNI is contraindicated | Not a first-line substitute for RAAS inhibition in other populations unless necessary |
Ivabradine | 5-7.5 mg BID | For patients with EF ≤35% in sinus rhythm with resting HR ≥70 bpm despite maximally tolerated beta-blocker | Does not work in atrial fibrillation (requires sinus rhythm) |
Loop Diuretics (chronic) | Furosemide 20-80 mg daily/BID; Bumetanide 0.5-2 mg daily/BID; Torsemide 10-20 mg daily | For symptom relief and volume management only; no mortality benefit | Adjust dose based on daily weight and fluid status |
ICD | N/A | Primary prevention ICD for EF ≤35% despite ≥3 months of optimal GDMT, NYHA II-III, expected survival >1 year | Do NOT place during the acute hospitalization; reassess EF after optimization |
CRT (Cardiac Resynchronization Therapy) | N/A | For EF ≤35% + LBBB with QRS ≥150 ms + NYHA II-IV on optimal GDMT | Greatest benefit with LBBB morphology and QRS ≥150 ms |
Acute phase: The immediate priority for a patient presenting with AHF is to address oxygenation, perfusion, and congestion. Most patients (roughly 70%) present as warm and wet, meaning they are congested but still maintaining adequate blood pressure and perfusion. For these patients, the first-line therapy is IV loop diuretics. Furosemide is the most commonly used agent. For a diuretic-naive patient, start with 20-40 mg IV bolus. For a patient already on chronic oral furosemide, the recommended initial IV dose is 1 to 2.5 times their daily oral dose. Reassess urine output within 2 hours. If the response is inadequate (urine output <100-150 mL/hr in the first 2 hours), double the dose and re-administer. If still refractory, consider adding a thiazide diuretic (metolazone 2.5-5 mg PO) for sequential nephron blockade, or transition to a continuous furosemide infusion (5-40 mg/hr).
If the patient is hypertensive (SBP >140 mmHg), adding an IV vasodilator is beneficial. IV nitroglycerin (starting at 5-10 mcg/min and titrating upward by 5-10 mcg/min every 5 minutes) reduces preload and, at higher doses, afterload. Sodium nitroprusside (starting at 0.3 mcg/kg/min) is a potent arterial and venous dilator useful in hypertensive crisis with AHF, but it requires arterial line monitoring and carries the risk of cyanide toxicity with prolonged use. Nesiritide (recombinant BNP) was previously used but has fallen out of favor due to lack of mortality benefit.
For patients in respiratory distress with pulmonary edema, non-invasive positive pressure ventilation (NIPPV) with BiPAP or CPAP is a critical intervention. It reduces preload, reduces work of breathing, recruits collapsed alveoli, and improves oxygenation. NIPPV has been shown to reduce the need for intubation and is the preferred respiratory support unless the patient is obtunded, unable to protect the airway, or failing non-invasive strategies.
For the cold and wet patient (low cardiac output with congestion), IV diuretics alone are insufficient and may worsen hypotension. These patients require inotropic support. Dobutamine (a beta-1 agonist, 2-20 mcg/kg/min) is the first-line inotrope, increasing cardiac contractility and output. Milrinone (a phosphodiesterase-3 inhibitor, 0.375-0.75 mcg/kg/min) is an alternative that provides both inotropy and vasodilation, but it must be used cautiously in renal impairment and can cause more hypotension. If the patient is in frank cardiogenic shock with SBP below 80-85 mmHg, norepinephrine (0.1-0.5 mcg/kg/min) is now the preferred first-line vasopressor based on the SOAP II trial, which showed lower mortality compared to dopamine in cardiogenic shock.
The most important "do not" in acute management: Do NOT initiate beta-blockers during acute decompensation. Beta-blockers are a cornerstone of chronic HFrEF management, but starting them when the patient is acutely congested or hemodynamically unstable can precipitate cardiogenic shock. If the patient is already on a beta-blocker at home, it can usually be continued at the same or reduced dose unless the patient is in shock, significantly bradycardic, or profoundly hypotensive.
Transition to long-term therapy: Once the patient is stabilized, euvolemic, and ready for discharge, the focus shifts to initiating and titrating the four pillars of GDMT for HFrEF: (1) ARNI (or ACEi/ARB), (2) beta-blocker, (3) MRA, and (4) SGLT2 inhibitor. Current guidelines recommend initiating all four classes during the index hospitalization (when hemodynamically stable) rather than sequential outpatient titration, as early initiation improves outcomes. Device therapy (ICD, CRT) is reassessed after at least 3 months of optimal GDMT, because EF may recover sufficiently to no longer meet criteria.
05Differential Diagnosis and Distractors
COPD Exacerbation
Why It Is Similar
Acute dyspnea, wheezing, hypoxemia; may have bilateral crackles if concurrent infection
Key Discriminator
History of smoking/COPD; wheezing (not crackles) predominates; hyperinflated lungs on CXR (not cephalization or Kerley B lines); low/normal BNP; no S3 or JVD
Pneumonia
Why It Is Similar
Dyspnea, crackles on auscultation, hypoxemia, abnormal CXR
Key Discriminator
Fever, productive cough with purulent sputum; focal (not bilateral diffuse) infiltrate on CXR; elevated WBC and procalcitonin; normal BNP
Pulmonary Embolism
Why It Is Similar
Acute dyspnea, hypoxemia, tachycardia; can cause right heart failure
Key Discriminator
Sudden onset, pleuritic chest pain, unilateral leg swelling; risk factors (immobilization, surgery, OCP); CXR often clear or with wedge-shaped infarct; elevated D-dimer; CT pulmonary angiography confirms diagnosis
ARDS
Why It Is Similar
Bilateral pulmonary infiltrates on CXR, severe hypoxemia, respiratory distress
Key Discriminator
Occurs in setting of identifiable trigger (sepsis, aspiration, trauma, pancreatitis); PCWP is normal (≤18 mmHg), distinguishing from cardiogenic pulmonary edema; ratio ≤300
Nephrotic Syndrome
Why It Is Similar
Bilateral lower extremity edema, weight gain, fluid overload
Key Discriminator
Severe proteinuria (>3.5 g/day), hypoalbuminemia, hyperlipidemia; no elevated JVP, no S3 gallop; normal BNP; normal cardiac function on echo
Cardiac Tamponade
Why It Is Similar
Hypotension, JVD, dyspnea
Key Discriminator
Beck's triad (hypotension, JVD, muffled heart sounds); pulsus paradoxus >10 mmHg; electrical alternans on ECG; large pericardial effusion on echo with diastolic collapse of right-sided chambers; lung fields are clear
Acute Exacerbation of Asthma
Why It Is Similar
Acute dyspnea, tachypnea, respiratory distress
Key Discriminator
Younger patient, history of atopy; diffuse expiratory wheezing (not crackles); CXR shows hyperinflation, no pulmonary edema; normal BNP
Differential | Why It Is Similar | Key Discriminator |
|---|---|---|
COPD Exacerbation | Acute dyspnea, wheezing, hypoxemia; may have bilateral crackles if concurrent infection | History of smoking/COPD; wheezing (not crackles) predominates; hyperinflated lungs on CXR (not cephalization or Kerley B lines); low/normal BNP; no S3 or JVD |
Pneumonia | Dyspnea, crackles on auscultation, hypoxemia, abnormal CXR | Fever, productive cough with purulent sputum; focal (not bilateral diffuse) infiltrate on CXR; elevated WBC and procalcitonin; normal BNP |
Pulmonary Embolism | Acute dyspnea, hypoxemia, tachycardia; can cause right heart failure | Sudden onset, pleuritic chest pain, unilateral leg swelling; risk factors (immobilization, surgery, OCP); CXR often clear or with wedge-shaped infarct; elevated D-dimer; CT pulmonary angiography confirms diagnosis |
ARDS | Bilateral pulmonary infiltrates on CXR, severe hypoxemia, respiratory distress | Occurs in setting of identifiable trigger (sepsis, aspiration, trauma, pancreatitis); PCWP is normal (≤18 mmHg), distinguishing from cardiogenic pulmonary edema; ratio ≤300 |
Nephrotic Syndrome | Bilateral lower extremity edema, weight gain, fluid overload | Severe proteinuria (>3.5 g/day), hypoalbuminemia, hyperlipidemia; no elevated JVP, no S3 gallop; normal BNP; normal cardiac function on echo |
Cardiac Tamponade | Hypotension, JVD, dyspnea | Beck's triad (hypotension, JVD, muffled heart sounds); pulsus paradoxus >10 mmHg; electrical alternans on ECG; large pericardial effusion on echo with diastolic collapse of right-sided chambers; lung fields are clear |
Acute Exacerbation of Asthma | Acute dyspnea, tachypnea, respiratory distress | Younger patient, history of atopy; diffuse expiratory wheezing (not crackles); CXR shows hyperinflation, no pulmonary edema; normal BNP |
06Traps and High-Yield Pearls
The most common way students get questions about acute heart failure wrong falls into a few predictable patterns:
Starting beta-blockers in acute decompensation. This is the single most tested "trap." A question will describe a patient in florid pulmonary edema with tachycardia, and one answer choice will be metoprolol. Students who know that beta-blockers are a pillar of HF management often select this answer. The correct approach is to stabilize first with IV diuretics and vasodilators, and start or resume beta-blockers only after the patient is euvolemic and hemodynamically stable.
Confusing cardiogenic pulmonary edema with ARDS. Both present with bilateral white-out on CXR and severe hypoxemia. The critical discriminator is the PCWP: elevated (>18 mmHg) in cardiogenic edema, normal in ARDS. An elevated BNP, S3 gallop, JVD, and identifiable cardiac history point to a cardiogenic cause. ARDS will have a clear non-cardiac trigger (sepsis, aspiration, trauma) and a ratio at or below 300.
Choosing dopamine over norepinephrine in cardiogenic shock. Older resources recommend dopamine, but current evidence (SOAP II trial) favors norepinephrine as the first-line vasopressor in cardiogenic shock due to fewer arrhythmic side effects and lower mortality.
Forgetting to check for and treat the precipitant. A vignette may describe AHF, but the "next best step" is not always furosemide. If the patient has new ST elevations, the answer is emergent catheterization. If they have rapid atrial fibrillation, rate control is essential. If they are nonadherent, management includes diuresis and education. Always identify the trigger.
Misinterpreting BNP in obese patients or renal failure. BNP levels are falsely low in obesity (adipose tissue clears natriuretic peptides) and falsely elevated in renal insufficiency. A "normal" BNP in a morbidly obese patient does not rule out heart failure, and a mildly elevated BNP in dialysis-dependent CKD does not confirm it.
Placing an ICD during the acute hospitalization. A question may describe a patient with a new EF of 20%. Students often choose ICD placement. The correct answer is to optimize GDMT for at least 3 months and then reassess, because EF may improve with medical therapy (especially in newly diagnosed non-ischemic cardiomyopathy).
The core competency being tested across AHF questions is the ability to classify the patient hemodynamically (warm/cold, wet/dry), match therapy to that profile, and sequence interventions correctly: stabilize first, treat the precipitant, and initiate long-term disease-modifying therapy only when the patient is ready.